FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133875784> ?p ?o ?g. }

• W2133875784 endingPage "2025" @default.
• W2133875784 startingPage "2015" @default.
• W2133875784 abstract "Survival after coronary artery bypass graft surgery (CABG) and medical therapy in patients with coronary artery disease (CAD) has been studied in both randomized trials and observational treatment comparisons. Over the past decade, the use of coronary angioplasty (PTCA) has increased dramatically, without guidance from either randomized trials or prospective observational comparisons. The purpose of this study was to describe the survival experience of a large prospective cohort of CAD patients treated with medicine, PTCA, or CABG.The study was designed as a prospective nonrandomized treatment comparison in the setting of an academic medical center (tertiary care). Subjects were 9263 patients with symptomatic CAD referred for cardiac catheterization (1984 through 1990). Patients with prior PTCA or CABG, valvular or congenital disease, nonischemic cardiomyopathy, or significant (> or = 75%) left main disease were excluded. Baseline clinical, laboratory, and catheterization data were collected prospectively in the Duke Cardiovascular Disease Databank. All patients were contacted at 6 months, 1 year, and annually thereafter (follow-up 97% complete). Cardiovascular death was the primary end point. Of this cohort, 2788 patients were treated with PTCA (2626 within 60 days) and 3422 with CABG (3080 within 60 days). Repeat or crossover revascularization procedures were counted as part of the initial treatment strategy. Kaplan-Meier survival curves (both unadjusted and adjusted for all known imbalances in baseline prognostic factors) were used to examine absolute survival differences, and treatment pair hazard ratios from the Cox model were used to summarize average relative survival benefits. For the latter, a 13-level CAD prognostic index was used to examine the relation between survival and revascularization as a function of CAD severity. The effects of revascularization on survival depended on the extent of CAD. For the least severe forms of CAD (ie, one-vessel disease), there were no survival advantages out to 5 years for revascularization over medical therapy. For intermediate levels of CAD (ie, two-vessel disease), revascularization was associated with higher survival rates than medical therapy. For less severe forms of two-vessel disease, PTCA had a small advantage over CABG, whereas for the most severe form of two-vessel disease (with a critical lesion of the proximal left anterior descending artery), CABG was superior. For the most severe forms of CAD (ie, three-vessel disease), CABG provided a consistent survival advantage over medicine. PTCA appeared prognostically equivalent to medicine in these patients, but the number of PTCA patients in this subgroup was low.In this first large-scale, prospective observational treatment comparison of PTCA, CABG, and medicine, we confirmed the previously reported survival advantages for CABG over medical therapy for three-vessel disease and severe two-vessel disease. For less severe CAD, the primary treatment choices are between medicine and PTCA. In these patients, there is a trend for a relative survival advantage with PTCA, although absolute survival differences were modest. In this setting, treatment decisions should be based not only on survival differences but also on symptom relief, quality of life outcomes, and patient preferences." @default.
• W2133875784 created "2016-06-24" @default.
• W2133875784 creator A5007508560 @default.
• W2133875784 creator A5017166084 @default.
• W2133875784 creator A5022026757 @default.
• W2133875784 creator A5023757786 @default.
• W2133875784 creator A5042352003 @default.
• W2133875784 creator A5051622829 @default.
• W2133875784 creator A5059200202 @default.
• W2133875784 creator A5059303252 @default.
• W2133875784 creator A5060829829 @default.
• W2133875784 creator A5070730630 @default.
• W2133875784 date "1994-05-01" @default.
• W2133875784 modified "2023-10-03" @default.
• W2133875784 title "Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty." @default.
• W2133875784 cites W1966292120 @default.
• W2133875784 cites W1979300931 @default.
• W2133875784 cites W1982448354 @default.
• W2133875784 cites W1989377468 @default.
• W2133875784 cites W1989456091 @default.
• W2133875784 cites W1999111531 @default.
• W2133875784 cites W2010038681 @default.
• W2133875784 cites W2022456908 @default.
• W2133875784 cites W2037398270 @default.
• W2133875784 cites W3139975823 @default.
• W2133875784 doi "https://doi.org/10.1161/01.cir.89.5.2015" @default.
• W2133875784 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8181125" @default.
• W2133875784 hasPublicationYear "1994" @default.
• W2133875784 type Work @default.
• W2133875784 sameAs 2133875784 @default.
• W2133875784 citedByCount "371" @default.
• W2133875784 countsByYear W21338757842012 @default.
• W2133875784 countsByYear W21338757842013 @default.
• W2133875784 countsByYear W21338757842014 @default.
• W2133875784 countsByYear W21338757842015 @default.
• W2133875784 countsByYear W21338757842016 @default.
• W2133875784 countsByYear W21338757842017 @default.
• W2133875784 countsByYear W21338757842018 @default.
• W2133875784 countsByYear W21338757842019 @default.
• W2133875784 countsByYear W21338757842020 @default.
• W2133875784 countsByYear W21338757842021 @default.
• W2133875784 countsByYear W21338757842022 @default.
• W2133875784 countsByYear W21338757842023 @default.
• W2133875784 crossrefType "journal-article" @default.
• W2133875784 hasAuthorship W2133875784A5007508560 @default.
• W2133875784 hasAuthorship W2133875784A5017166084 @default.
• W2133875784 hasAuthorship W2133875784A5022026757 @default.
• W2133875784 hasAuthorship W2133875784A5023757786 @default.
• W2133875784 hasAuthorship W2133875784A5042352003 @default.
• W2133875784 hasAuthorship W2133875784A5051622829 @default.
• W2133875784 hasAuthorship W2133875784A5059200202 @default.
• W2133875784 hasAuthorship W2133875784A5059303252 @default.
• W2133875784 hasAuthorship W2133875784A5060829829 @default.
• W2133875784 hasAuthorship W2133875784A5070730630 @default.
• W2133875784 hasBestOaLocation W21338757841 @default.
• W2133875784 hasConcept C126322002 @default.
• W2133875784 hasConcept C141071460 @default.
• W2133875784 hasConcept C164705383 @default.
• W2133875784 hasConcept C168563851 @default.
• W2133875784 hasConcept C188816634 @default.
• W2133875784 hasConcept C207103383 @default.
• W2133875784 hasConcept C2777385415 @default.
• W2133875784 hasConcept C2778213512 @default.
• W2133875784 hasConcept C2779464278 @default.
• W2133875784 hasConcept C2780326628 @default.
• W2133875784 hasConcept C44249647 @default.
• W2133875784 hasConcept C500558357 @default.
• W2133875784 hasConcept C71924100 @default.
• W2133875784 hasConcept C72563966 @default.
• W2133875784 hasConceptScore W2133875784C126322002 @default.
• W2133875784 hasConceptScore W2133875784C141071460 @default.
• W2133875784 hasConceptScore W2133875784C164705383 @default.
• W2133875784 hasConceptScore W2133875784C168563851 @default.
• W2133875784 hasConceptScore W2133875784C188816634 @default.
• W2133875784 hasConceptScore W2133875784C207103383 @default.
• W2133875784 hasConceptScore W2133875784C2777385415 @default.
• W2133875784 hasConceptScore W2133875784C2778213512 @default.
• W2133875784 hasConceptScore W2133875784C2779464278 @default.
• W2133875784 hasConceptScore W2133875784C2780326628 @default.
• W2133875784 hasConceptScore W2133875784C44249647 @default.
• W2133875784 hasConceptScore W2133875784C500558357 @default.
• W2133875784 hasConceptScore W2133875784C71924100 @default.
• W2133875784 hasConceptScore W2133875784C72563966 @default.
• W2133875784 hasIssue "5" @default.
• W2133875784 hasLocation W21338757841 @default.
• W2133875784 hasLocation W21338757842 @default.
• W2133875784 hasOpenAccess W2133875784 @default.
• W2133875784 hasPrimaryLocation W21338757841 @default.
• W2133875784 hasRelatedWork W1973590076 @default.
• W2133875784 hasRelatedWork W1979219809 @default.
• W2133875784 hasRelatedWork W2026078933 @default.
• W2133875784 hasRelatedWork W2040172628 @default.
• W2133875784 hasRelatedWork W2049626142 @default.
• W2133875784 hasRelatedWork W2123619855 @default.
• W2133875784 hasRelatedWork W2385155423 @default.
• W2133875784 hasRelatedWork W3106725299 @default.
• W2133875784 hasRelatedWork W3151951029 @default.
• W2133875784 hasRelatedWork W4377264023 @default.

• next